Trial Profile
A randomized, placebo-controlled phase II clinical trial of combination erlotinib (Tarceva) and celecoxib (Celebrex) versus erlotinib (Tarceva)/placebo in advanced non-small cell lung cancer patients.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Celecoxib (Primary) ; Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Therapeutic Use
- 19 Dec 2016 Status changed from active, no longer recruiting to completed.
- 10 Feb 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Oct 2017, according to ClinicalTrials.gov record.
- 30 Jul 2015 Planned primary completion date changed from 1 Oct 2015 to 1 Oct 2016 as reported by ClinicalTrials.gov.